Arcus Biosciences Inc (RCUS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Arcus Biosciences Inc stock (RCUS) is currently trading at $20.25. Arcus Biosciences Inc PS ratio (Price-to-Sales) is 10.98. Analyst consensus price target for RCUS is $33.80. WallStSmart rates RCUS as Sell.
- RCUS PE ratio analysis and historical PE chart
- RCUS PS ratio (Price-to-Sales) history and trend
- RCUS intrinsic value — DCF, Graham Number, EPV models
- RCUS stock price prediction 2025 2026 2027 2028 2029 2030
- RCUS fair value vs current price
- RCUS insider transactions and insider buying
- Is RCUS undervalued or overvalued?
- Arcus Biosciences Inc financial analysis — revenue, earnings, cash flow
- RCUS Piotroski F-Score and Altman Z-Score
- RCUS analyst price target and Smart Rating
Arcus Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Arcus Biosciences Inc (RCUS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Arcus Biosciences Inc (RCUS) Key Strengths (3)
74.46% of shares held by major funds and institutions
Strong revenue growth at 26.90% annually
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Arcus Biosciences Inc (RCUS) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 11.0x annual revenue
Premium pricing at 4.3x book value
Supporting Valuation Data
Arcus Biosciences Inc (RCUS) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 8.3/10) while 5 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Revenue Growth, Market Cap. Growth metrics are encouraging with Revenue Growth at 26.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (10.98), Price/Book (4.30) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -63.30%, Operating Margin at -345.40%, Profit Margin at -142.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -63.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 26.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RCUS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RCUS's Price-to-Sales ratio of 10.98x trades at a deep discount to its historical average of 161.2x (23th percentile). The current valuation is 99% below its historical high of 1422.93x set in May 2018, and 188% above its historical low of 3.81x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~3.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Arcus Biosciences Inc (RCUS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Arcus Biosciences Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 247M with 27% growth year-over-year. The company is currently unprofitable, posting a -142.9% profit margin.
Key Findings
Revenue growing at 27% YoY, reaching 247M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.25 indicates a conservative balance sheet with 238M in cash.
The company is unprofitable with a -142.9% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -121M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Arcus Biosciences Inc maintain 27%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Arcus Biosciences Inc.
Bottom Line
Arcus Biosciences Inc offers an attractive blend of growth (27% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Arcus Biosciences Inc(RCUS)
NYSE
HEALTHCARE
BIOTECHNOLOGY
USA
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.